Brinton gets nod from DCGI for favipiravir in India

Advt.

Pharma Company, Brinton Pharmaceuticals has received green signal from Drugs Controller General of India (DCGI) for marketing of favipiravir under the brand name faviton. The drug will be marketed in India and exported globally by the company and will be available in 200 mg tablets.

Favipiravir is an effective treatment option in the management of mild-to-moderate COVID-19 as per clinical evidence. The medicine is an orally-administered medication and more convenient compared to intravenously-administered medicines.

Rahul Kumar Darda, CMD, Brinton Pharmaceuticals, said, “We always wanted to launch “evidence-based cure” to combat COVID-19. Our strategic intent will be to improve the access through our strong distribution network that will help make faviton available across all COVID treatment centres and our MRP is Rs 59 per tablet”.

The drug will be available in a strip of 10 tablets and 50 tablets in a box.

LEAVE A REPLY

Please enter your comment!
Please enter your name here